Press Release VOLUNTIS AND ASTRAZENECA TO TEST COMPANION MOBILE APP IN OVARIAN CANCER STUDIES WITH THE US NATIONAL CANCER INSTITUTE 7 December 2015 Voluntis and AstraZeneca today announced plans to test a digital support

Source URL: www.voluntis.com

• Chemistry
• Organic chemistry
• Cancer
• RTT
• PARP inhibitors
• Lactams
• Indoles
• Olaparib
• Piperazines
• Cediranib
• AstraZeneca
• Ovarian cancer